Neoantigen × AI
Daily research signal
№60Brief

Neoantigen-selected TILs enter phase 1 for ICB-resistant tumors

Today's throughline is selection quality: a Vall d'Hebron early-phase 1 trial is testing neoantigen-enriched TILs in ICB-resistant epithelial tumors, extending neoantigen selection from vaccines into cell therapy.trial

On the computational side, a Nature paper (HLA3DB) pushes epitope prioritization toward structure, while a Frontiers study warns that the field's workhorse tools, NetMHCpan-4.NatureFrontiers 1 and NetMHCIIpan-4.Frontiers 0, lose accuracy on non-European HLA alleles absent from training data.Frontiers For sponsors and platform companies, both the clinical hypothesis and the tooling bias bear directly on which neoantigens get manufactured.

1new story2 in context
ClinicaltodayNew

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

Vall d'Hebron Institute of Oncology is recruiting an early-phase 1 study of ex vivo next-generation neoantigen-selected TIL therapy in advanced epithelial tumors and ICB-resistant solid tumors. The product is an autologous, genetically unmodified TIL preparation enriched for neoantigen reactivity, administered with the standard non-myeloablative lymphodepleting chemotherapy plus IL-2 support described in the protocol background. The signal for the field: neoantigen selection is being applied as a manufacturing enrichment step for TIL-ACT, not just vaccine design, in a solid-tumor population where TIL efficacy remains unproven. Readout is safety and tolerability, an early gate for whether neoantigen-enriched TILs can move beyond melanoma.

clinicaltrials · today · Vall d'Hebron Institute of Oncology

02

Relevant work from earlier we're still surfacing — not today's news.